Tied, grouped continuous and ordered categorical data : a comparison of two models / per 390668 Pettitt, A. N.

Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication. per Evans, J, Ziebland, S, Pettitt, A

Schaum's outline of theory and problems of advanced mathematics for engineers and scientists / per 377809 Spiegel, Murray R., Pettitt, A. N.

Scalable Bayesian inference for the inverse temperature of a hidden Potts model per Moores, M, Nicholls, G, Pettitt, A, Mengersen, K

Appendix A: Legal framework on the scientific use of animals in research per Pettitt, D, Pettitt, A, Roberts, M, Smith, J, Brindley, D

Characterizing an outbreak of vancomycin-resistant enterococci using hidden Markov models. per McBryde, E, Pettitt, A, Cooper, B, McElwain, D

Identification of Novel Recurrent Copy Number Variations and Regions of Copy-Neutral Loss of Heterozygosity by High Resolution Genomic Array in Pre-Treatment and Relapsed B-CLL. per Knight, S, Akha, E, Timbs, A, Enver, T, Pettitt, A, Taylor, J, Hatton, C, Schuh, A

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial. per Catovsky, D, Richards, S, Matutes, E, Burford, A, Brito-Babapulle, V, Dearden, C, Morris, P, Pettitt, A

Prognostic factors in the UK LRF CLL4 trial per Oscier, D, Richards, S, Orchard, J, Davis, Z, Morilla, A, Brito-Bapapulle, V, Matutes, E, Pettitt, A, Catovsky, D

Prognostic factors in the UK LRF CLL4 trial. per Oscier, D, Richards, S, Orchard, J, Davis, Z, Best, G, Morilla, A, Brito-Bapapulle, V, Matutes, E, Pettitt, A, Catovsky, D

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. per Oscier, D, Dearden, C, Eren, E, Erem, E, Fegan, C, Follows, G, Hillmen, P, Illidge, T, Matutes, E, Milligan, D, Pettitt, A, Schuh, A, Wimperis, J

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. per Lin, K, Adamson, J, Johnson, G, Carter, A, Oates, M, Wade, R, Richards, S, Gonzalez, D, Matutes, E, Dearden, C, Oscier, D, Catovsky, D, Pettitt, A

Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. per Knight, S, Yau, C, Clifford, R, Timbs, A, Sadighi Akha, E, Dréau, H, Burns, A, Ciria, C, Oscier, D, Pettitt, A, Dutton, S, Holmes, C, Taylor, J, Cazier, J, Schuh, A

Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. per Knight, S, Yau, C, Clifford, R, Timbs, A, Sadighi Akha, E, Dréau, H, Burns, A, Ciria, C, Oscier, D, Pettitt, A, Dutton, S, Holmes, C, Taylor, J, Cazier, J, Schuh, A

Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia. per Rees-Unwin, K, Faragher, R, Unwin, R, Adams, J, Brown, P, Buckle, A, Pettitt, A, Hutchinson, C, Johnson, S, Pulford, K, Banham, A, Whetton, A, Lucas, G, Mason, D, Burthem, J

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-... per Hillmen, P, Pettitt, A, Schuh, A, Milligan, D, Bowles, K, Bareford, D, Riaz, J, Follows, G, Rule, S, Wallis, J, Gribben, J, Noble, R, Pocock, C, Lisby, S, Carey, J, Gupta, I, Chang, C, McKeown, A

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. per Catovsky, D, Richards, S, Matutes, E, Oscier, D, Dyer, M, Bezares, R, Pettitt, A, Hamblin, T, Milligan, D, Child, J, Hamilton, MS, Dearden, C, Smith, A, Bosanquet, A, Davis, Z, Brito-Babapulle, V, Else, M, Wade, R, Hillmen, P

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome per Roberts, C, Love, S, Eyre, T, Clifford, R, Boyle, L, Cabes, M, Schuh, A, Bloor, A, Collins, G, Devereux, S, Follows, G, Fox, C, Gribben, J, Hillmen, P, Hatton, C, Littlewood, T, McCarthy, H, Murray, J, Pettitt, A, Soilleux, E, Stamopoulos, B, Weatherspoon, A

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome per Eyre, T, Clifford, R, Bloor, A, Boyle, L, Roberts, C, Cabes, M, Collins, G, Devereux, S, Follows, G, Fox, C, Gribben, J, Hillmen, P, Hatton, C, Littlewood, T, Mccarthy, H, Murray, J, Pettitt, A, Soilleux, E, Stamatopoulos, B, Love, S, Wotherspoon, A, Schuh, A

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. per Chakraverty, R, Orti, G, Roughton, M, Shen, J, Fielding, A, Kottaridis, P, Milligan, D, Collin, M, Crawley, C, Johnson, P, Clark, A, Parker, A, Bloor, A, Pettengell, R, Snowden, J, Pettitt, A, Clark, R, Hale, G, Peggs, K, Thomson, K, Morris, E, Mackinnon, S